NR3C2 and chronic kidney disease: Initial evidence from the ARTS (MinerAlocorticoid Receptor Antagonist Tolerability Study) and ARTS-HF (MinerAlocorticoid Receptor antagonist Tolerability Study Heart Failure) studies demonstrated comparable reductions in natriuretic peptides and albuminuria with fewer hyperkalemia events compared to spironolactone or eplerenone in patients with HFrEF and mild-to-moderate CKD and/or T2DM [33,34].